Key Takeaway: Cognition Therapeutics is initiating a public offering to raise $11.5 million for its Alzheimer's drug. The offering reflects the company's ongoing efforts to fund its research and development initiatives. Further details about the offering and its implications for the company's future projects were not provided in the article.
Price reaction · baseline $2.07 (2024-06-11 close) · hit after-hours · 1 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+15%
day 1
+6.3%
day 3
+5.8%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.